Astellas Farma Lda

Astellas Farma Lda is the Portuguese commercial subsidiary of Astellas Pharma Inc., a Japanese global life sciences company. Based in Porto Salvo, near Lisbon, the entity operates as the local affiliate responsible for registering, marketing, and distributing Astellas medicines in Portugal. Its parent, Astellas Pharma Inc., was established in April 2005 through the merger of Yamanouchi Pharmaceutical (founded 1923) and Fujisawa Pharmaceutical (founded 1894), combining Yamanouchi's strengths in urological medications and chemical synthesis with Fujisawa's expertise in transplant/immunology and fermentation technology. Astellas describes itself as a global life sciences company committed to turning innovative science into VALUE for patients, with more than 13,500 employees worldwide and therapies that have reached more than 172 million patients in 103 countries and areas since its founding. The Portuguese affiliate is part of that international network, serving the local healthcare market under the Astellas brand and the group's corporate governance and strategic framework, including the Corporate Strategic Plan 2026 (CSP2026). As a subsidiary, Astellas Farma Lda does not have its own stock listing; its ultimate parent is listed on the Tokyo Stock Exchange under ticker 4503.

Astellas Farma Lda is the Portuguese affiliate of Astellas Pharma Inc., a company created in April 2005 through the merger of two Japanese pharmaceutical firms: Yamanouchi Pharmaceutical, founded in 1923, and Fujisawa Pharmaceutical, founded in 1894. The merger combined Yamanouchi's strengths in urological medications and chemical synthesis with Fujisawa's excellence in the transplant/immunology area and fermentation technology, forming what Astellas describes as an ideal complementary partnership. Astellas has since grown into a global life sciences company with more than 13,500 employees, and its therapies have reached more than 172 million patients in 103 countries and areas. The Portuguese entity, based in Porto Salvo, operates within this international structure as a local commercial and regulatory arm. It follows the group's corporate governance guidelines, which emphasize transparency, appropriateness, and agility of management, as well as fiduciary duties and accountability to shareholders. The affiliate also aligns with the group's Corporate Strategic Plan 2026 (CSP2026), a five-year plan guiding sustainable growth and the delivery of greater VALUE faster for patients. As a subsidiary, Astellas Farma Lda does not have its own public listing; its ultimate parent, Astellas Pharma Inc., is listed on the Tokyo Stock Exchange under ticker 4503.

• 2025

  Astellas celebrates its 20th anniversary as a company in April 2025.

• 2005

  Astellas Pharma Inc. is established in April through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.

• 1923

  Yamanouchi Pharmaceutical, the other predecessor company, is founded.

• 1894

  Fujisawa Pharmaceutical, one of Astellas's predecessor companies, is founded.

Local affiliate of a global life sciences company focused on turning innovative science into VALUE for patients.

Product categories. Prescription pharmaceuticals · Urology treatments · Transplant and immunology medicines · Oncology therapies

1. 1Homepage | Astellasastellas.com
2. 2History & Company Milestones | Astellasastellas.com
3. 3Corporate Governance Systems & Structure | Astellasastellas.com
4. 4Corporate Strategic Plan | Astellasastellas.com
5. 5Astellas Farma Lda (Portugal) - Wikidatawikidata.org